Ad-gBCMVpoly : A novel chimeric vaccine strategy for human cytomegalovirus-associated diseases
In spite of numerous attempts at successful licensure, a human cytomegalovirus (HCMV) vaccine formulation remains elusive. To overcome the limitations of previous strategies, we have recently developed a novel chimeric vaccine which allows induction of both humoral and cellular immune response following a single vaccination. This vaccine includes the extracellular domain of HCMV-encoded glycoprotein-B (gB) covalently linked to multiple HLA class I- and class II-restricted T-cell epitopes from multiple HCMV antigens as a contiguous polypeptide in a replication-deficient adenoviral vector Ad5/F35 (referred to as Ad-gBCMVpoly). Immunisation with Ad-gBCMVpoly consistently generated strong gB-specific neutralizing antibody and a broad range of HCMV-specific pluripotent CD8(+) and CD4(+) T-cells. This immunity suppressed infection with recombinant vaccinia virus encoding HCMV antigens. Furthermore, in vitro stimulation with Ad-gBCMVpoly rapidly expanded multiple antigen-specific human CD8(+) and CD4(+) T-cells from healthy virus carriers. Here we discuss the advantages of the Ad-gBCMVpoly vaccine and its potential application in different clinical settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 Suppl 4 |
|---|---|
| Enthalten in: |
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 46 Suppl 4(2009) vom: 15. Dez., Seite S68-72 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhong, Jie [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.02.2010 Date Revised 25.11.2009 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcv.2009.07.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM190373962 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM190373962 | ||
| 003 | DE-627 | ||
| 005 | 20231223185234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcv.2009.07.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0635.xml |
| 035 | |a (DE-627)NLM190373962 | ||
| 035 | |a (NLM)19646921 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhong, Jie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ad-gBCMVpoly |b A novel chimeric vaccine strategy for human cytomegalovirus-associated diseases |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2010 | ||
| 500 | |a Date Revised 25.11.2009 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In spite of numerous attempts at successful licensure, a human cytomegalovirus (HCMV) vaccine formulation remains elusive. To overcome the limitations of previous strategies, we have recently developed a novel chimeric vaccine which allows induction of both humoral and cellular immune response following a single vaccination. This vaccine includes the extracellular domain of HCMV-encoded glycoprotein-B (gB) covalently linked to multiple HLA class I- and class II-restricted T-cell epitopes from multiple HCMV antigens as a contiguous polypeptide in a replication-deficient adenoviral vector Ad5/F35 (referred to as Ad-gBCMVpoly). Immunisation with Ad-gBCMVpoly consistently generated strong gB-specific neutralizing antibody and a broad range of HCMV-specific pluripotent CD8(+) and CD4(+) T-cells. This immunity suppressed infection with recombinant vaccinia virus encoding HCMV antigens. Furthermore, in vitro stimulation with Ad-gBCMVpoly rapidly expanded multiple antigen-specific human CD8(+) and CD4(+) T-cells from healthy virus carriers. Here we discuss the advantages of the Ad-gBCMVpoly vaccine and its potential application in different clinical settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antigens, Viral |2 NLM | |
| 650 | 7 | |a Cytomegalovirus Vaccines |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Histocompatibility Antigens Class I |2 NLM | |
| 650 | 7 | |a Histocompatibility Antigens Class II |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 650 | 7 | |a Viral Envelope Proteins |2 NLM | |
| 650 | 7 | |a glycoprotein B, Simplexvirus |2 NLM | |
| 700 | 1 | |a Khanna, Rajiv |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology |d 1997 |g 46 Suppl 4(2009) vom: 15. Dez., Seite S68-72 |w (DE-627)NLM097223964 |x 1873-5967 |7 nnns |
| 773 | 1 | 8 | |g volume:46 Suppl 4 |g year:2009 |g day:15 |g month:12 |g pages:S68-72 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcv.2009.07.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 Suppl 4 |j 2009 |b 15 |c 12 |h S68-72 | ||